Exelixis' CEO Presents At 30th Annual JPMorgan Healthcare Conference - Conference Call Transcript

Exelixis, Inc. ( EXEL)

30th Annual JPMorgan Healthcare Conference Call

January 11, 2012 6:30 pm ET


Mike Morrissey - President and CEO

Charles Butler - VP, IR



Cory Kasimov

Good afternoon, everybody. I'm Cory Kasimov, the Senior Biotech Analyst at JPMorgan. And it's my pleasure to introduce our next company, which is Exelixis. Presenting for Exelixis will be the President and CEO, Mike Morrissey. And following Mike's presentation, there will be a breakout down the hall in the Olympic Room. So Mike?

Mike Morrissey

So before I start, Charles Butler, our VP of IR, will read a brief forward-looking statement.

Charles Butler

During the course of this presentation, we'll be making forward-looking statements regarding future events and future performance of the company. Actual events and results of course could differ materially. We refer you to the documents that Exelixis files from time to time with the Securities and Exchange Commission, specifically the company's most recent Form 10-Q filed on October 27, 2011. These documents contain and identify under the heading Risk Factors important factors that could cause actual results to differ materially from those contained in any forward-looking statements including risks related to the potential failure of cabozantinib to demonstrate safety and efficacy in clinical testing, our ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion, the sufficiency of Exelixis' capital and other resources and any uncertainty of the FDA review and approval process.

If you liked this article you might like

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Carnival, Tableau Software, Groupon, Newell Brands: 'Mad Money' Lightning Round

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Exelixis Has an Enviable Chart Pattern

Biotech Movers: Exelixis, Omeros, Inovio